FDA Finalizes Guidance on GDUFA II

The US Food and Drug Administration (FDA) on Tuesday finalized guidance to help sponsors understand how the review goals established as part of the Generic Drug User Fee Amendments Reauthorization of 2017 (GDUFA II) apply to amendments to either abbreviated new drug applications (ANDAs) or prior approval supplements (PASs).